[Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib...

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard treatment for non-small cell lung cancer (NSCLC) with activating EGFR mutations.
• Resistance to first- and second-generation EGFR-TKIs, often due to the T790M mutation, limits long-term efficacy.
• There is a significant unmet need for therapies that overcome acquired resistance to EGFR-TKIs.

Purpose of the Study:

• To review the development of third-generation EGFR-TKIs.
• To highlight Osimertinib as the first approved third-generation EGFR-TKI in Germany.
• To discuss the importance of molecular diagnostics for guiding treatment decisions.

Main Methods:

• Review of clinical development of third-generation EGFR-TKIs.
• Focus on Osimertinib's clinical efficacy and safety profile.
• Discussion of molecular testing methods, including tumor tissue and circulating tumor DNA (ctDNA).

Main Results:

• Third-generation EGFR-TKIs demonstrate clinical efficacy with manageable side effects.
• Osimertinib has shown relevant clinical activity and is approved in Germany.
• Molecular testing is essential for patient selection for third-generation EGFR-TKI therapy.

Conclusions:

• Third-generation EGFR-TKIs represent a significant advancement in NSCLC treatment.
• Osimertinib is a key therapeutic option for patients with EGFR-mutated NSCLC, particularly those with T790M resistance.
• Molecular diagnostics are indispensable for personalized treatment strategies in NSCLC.